News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Lisa D. Eli

Articles by Lisa D. Eli

TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study

ByPooja Advani, MBBS, MD,Sofia Braga,Adam M. Brufsky, MD, PhD,Karthik V. Giridhar,Erica L. Mayer, MD, MPH,Kelly E. McCann,Ruth M. O’Regan,Cristina Saura,Seth A. Wander,Georg F. Bischof,Beth H. Lowenthal,Judith D. Bebchuk,Lisa D. Eli,Brian G. Barnett,Joyce A. O’Shaughnessy,Tufia C. Haddad

April 11th 2025

Latest Updated Articles

Trending on CancerNetwork

Prophylaxis and Practical Implementation of the COPERNICUS Approach

Pirtobrutinib Monotherapy Earns Canadian Approval in Lymphoma/Leukemia Populations

Palbociclib Maintenance Extends PFS in HR+/HER2+ Advanced Breast Cancer

FDA Receives NDA for Lirafugratinib in 2L FGR2-Mutated Cholangiocarcinoma

New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma